{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Surgical+Resection+of+Melanoma&page=4", "query": { "intervention": "Surgical Resection of Melanoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 130, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Surgical+Resection+of+Melanoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Surgical+Resection+of+Melanoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T11:30:42.324Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04875728", "title": "The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Pathologic Stage I Cutaneous Melanoma AJCC v8", "Pathologic Stage IA Cutaneous Melanoma AJCC v8", "Pathologic Stage IB Cutaneous Melanoma AJCC v8", "Pathologic Stage II Cutaneous Melanoma AJCC v8", "Pathologic Stage IIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIC Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Cefazolin", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-09-08", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04875728" }, { "nct_id": "NCT05059444", "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma", "Ureter Carcinoma", "Renal Pelvis Carcinoma", "Non-small Cell Lung Cancer", "Invasive Breast Carcinoma", "Cutaneous Melanoma", "Esophageal Carcinoma", "Gastroesophageal Junction Carcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Endometrial Carcinoma", "Renal Cell Carcinoma", "Rectal Adenocarcinoma", "Colon Adenocarcinoma" ], "interventions": [ { "name": "Guardant Reveal", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Guardant Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2285, "start_date": "2021-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059444" }, { "nct_id": "NCT05704933", "title": "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Melanoma", "Metastasis to Brain" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Standard of Care Craniotomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-06-06", "completion_date": "2024-08-20", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 2, "location_summary": "Tampa, Florida • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704933" }, { "nct_id": "NCT02613325", "title": "fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pigmented Skin Lesion", "Melanoma" ], "interventions": [ { "name": "Functional photoacoustic microscopy", "type": "DEVICE" }, { "name": "Standard of care surgical excision", "type": "PROCEDURE" }, { "name": "Single cell photoacoustic microscopy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-06-08", "completion_date": "2017-06-27", "has_results": false, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02613325" }, { "nct_id": "NCT01886235", "title": "Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Melanoma", "Stage IA Skin Melanoma", "Stage IB Skin Melanoma", "Stage IIA Skin Melanoma", "Stage IIB Skin Melanoma", "Stage IIC Skin Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Diagnostic Microscopy", "type": "PROCEDURE" }, { "name": "Fluorescein Sodium Injection", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-09-04", "completion_date": "2020-05-06", "has_results": true, "last_update_posted_date": "2020-08-07", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01886235" }, { "nct_id": "NCT04117373", "title": "Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Skin Cancer", "Mohs Micrographic Surgery", "Interpolated Flap Repair" ], "interventions": [], "intervention_types": [], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "1 Year", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Year to 99 Years" }, "enrollment_count": 0, "start_date": "2019-07-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-03-06", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04117373" }, { "nct_id": "NCT06557291", "title": "Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "BRAF V600 Mutated-Stage III/IV Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2022-10-04", "completion_date": "2023-11-16", "has_results": false, "last_update_posted_date": "2024-08-16", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06557291" }, { "nct_id": "NCT01682213", "title": "Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 23, "start_date": "2012-09", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2020-05-26", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682213" }, { "nct_id": "NCT06673095", "title": "Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Excision", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2024-12-11", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 5, "location_summary": "Davis, California • Lexington, Kentucky • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673095" }, { "nct_id": "NCT04930783", "title": "NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "CDX-301", "type": "DRUG" }, { "name": "NEOVAX", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-01-03", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-06T11:30:42.324Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04930783" } ] }